Business
Flameret, Inc. Begins Shipping Orders as Initial Order Flow for Cannadol Hemp Oil Exceeds Internal Expectations
Flameret, Inc. Begins Shipping Orders as Initial Order Flow for Cannadol Hemp Oil Exceeds Internal Expectations.
About this update from Flameret Inc
[{"type":"text","content":"\n\n\n\nFlameret, Inc. Begins Shipping Orders as Initial Order Flow for Cannadol Hemp Oil Exceeds Internal Expectations\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nFlameret, Inc. Begins Shipping Orders as Initial Order Flow for Cannadol Hemp Oil Exceeds Internal Expectations\nCompany Plans on Introducing Second CBD (\"Cannabidiol\") Product Within Days\nCompany to Open Amazon Webstore to Further Drive Online Revenues\nPR Newswire\nVENICE, Fla., Sept. 10, 2014\n\n\n\n\n\n\n\n\n\nVENICE, Fla., Sept. 10, 2014 /PRNewswire/ -- Flameret, Inc. (OTC: FLRE) announced today that Royal Hemp Corporation, its wholly-owned Colorado subsidiary, has begun shipping high CBD hemp oil orders. The company previously announced the launch of Cannadol™, its high CBD (cannabidiol) hemp oil. Over the first three days after the product launch was announced, the company received orders from 21 different customers. Further details regarding initial revenues will be announced in the company's financial statements that will be filed at http://www.otcmarkets.com.\n\nCannadol™ is a dietary supplement sold as a hemp oil rich in CBD. It consists of 200mg of cannabidiol cold pressed from industrial hemp in an oral suspension of 1 ounce of hemp oil. None of the statements regarding Cannadol™ or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.Scientific and clinical studies continue to underscore CBD's potential as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic capabilities, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.John Meredith, Chief Executive Officer of Flameret, Inc. remarked, \"The launch of Cannadol™ and the response from consumers has far surpassed our internal expectations. We expect to deliver more good news to the invest...